Global Men and HIV Technical Working Group (MENHT) Men and PrEP webinar series April 13th, 2023

Reaching men with pharmacy-based HIV PrEP delivery in Kenya

Alexandra Kuo, PharmDc

Department of Pharmacy, University of Washington, Seattle, USA

Victor Omollo, MBChB, MPH

Kenya Medical Research Institute, Center for Microbiology Research, Nairobi, Kenya

Principal Investigators:

- Katrina F. Ortblad, ScD, MPH. Fred Hutchinson Cancer Center, Seattle, USA
- Kenneth Ngure, MPH, EMOD, MSc, PhD. Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya
- Elizabeth Bukusi, MPH, PhD, PGD, MA, CIP, FAAS. Kenya Medical Research Institute, Nairobi, Kenya



Background

- In many African settings, HIV pre-exposure prophylaxis (PrEP) is primarily delivered at healthcare facilities, with quarterly clinic visits for HIV testing prior to PrEP refills.
- In these settings, men often engage less with facility-based HIV services compared to women (who often access facilities for family planning and antenatal care services).
 - This often results in men less likely to access preventive services, more likely to present with late-stage HIV (resulting in higher mortality), and more likely to drop out of HIV care services
- Differentiated, community-based models of HIV service delivery that operate outside healthcare facilities might be better suited for reaching men
 - In these settings, men often have economic power and can potentially pay for HIV services outside the public sector
 - Private, retail pharmacies are ubiquitous in many African settings and have been underutilized for HIV service delivery; delivering HIV services here might help reach men.

Potential of pharmacy-delivered PrEP services







at a public HIV clinic

(Ortblad KF, et. al., JIAS 2020)



Associated with visiting HIV clinics when HIV uninfected



Limited hours of operation

Especially challenging for workers



Long wait times & travel distance

Associated with overcrowding, multiple PrEP stops, and limited PrEP clinics

Lack of privacy

Associated with overcrowding and HIV-specific health service provision

Design of a pharmacy PrEP delivery model

- Collaboratively developed with Kenyan stakeholders in a one-day meeting (Jan 2020)
- Model informed by formative qualitative research and adapted from a model of pharmacy-delivered PrEP services ongoing in Seattle, USA (One-Step PrEP)
- Pharmacy providers deliver PrEP using a prescribing checklist overseen by a remote clinician; this checklist includes:
 - HIV risk assessment; assessment of PrEP safety/medical eligibility; HIV testing; PrEP dispensing; referral (when necessary)



Pilot studies in Kenya



Clinic-initiated PrEP w/ pharmacy providerdelivered refills

(CFAR NIA; PI: Ortblad)



Pharmacy providerdelivered PrEP initiation & refills

(NIMH R34; PI: Ortblad)

Pharmacy PrEP refill (PPR) pilot in Kenya

Thika, Kenya: 2 retail pharmacies, 2 public clinics



(Mogere P, et. al., CROI 2023)

Study procedures:

• Clients initiate PrEP at a public HIV clinic with option for PrEP refills at:

∎₽∎

a:

- At the same public clinic
- At one of two nearby pharmacies
- <u>Pharmacies</u>: licensed, trained on PrEP delivery, & have private room
- <u>Eligible clients</u>: >18 years, at HIV risk, & meet all eligibility on PrEP prescribing checklist
- Cost: 300 KSH (~\$3 USD) per visit at pharmacy, free at clinics



PPR: study participants





PPR: PrEP initiation & continuation



All participants, n=106



(Mogere P, et. al., CROI 2023)

PPR: PrEP initiation & continuation, by sex



Pharmacy PrEP initiation (PPI) pilot in Kenya





(Ortblad KF, et. al., CROI 2022)

Thika, Kenya: 2 retail pharmacies Kisumu, Kenya: 2 retail pharmacies



- <u>Pharmacies</u>: must be licensed, certified to deliver providerassisted HIVST, & have private room
- <u>Eligible clients</u>: >18 years, at HIV risk, & meet all eligibility on PrEP prescribing checklist
- <u>Recruitment</u>: posters, pharmacy providers, word-of-mouth
- Cost: 300 KSH (~\$3 USD) for each pharmacy PrEP visit

PPI: Care pathway for pharmacy PrEP delivery



PPI: Study participants



PPI: Client behaviors associated with HIV risk



	All clients (N=287)			Clients <25 years		Clients ≥25 years	
				Women (N=64)	Men (N=60)	Women (N=59)	Men (N=104)
Partner (s) with HIV	<mark>3%</mark> 3%			3%	0%	5%	4%
Partner(s) HIV unknown			84%	80%	88%	85%	83%
Inconsistent condom use			72%	25%	75%	27%	71%
Multiple sexual partners		53%		75%	68%	80%	69%
Recent sex with alcohol	27%			13%	40%	8%	39%
Transactional sex	12%			11%	10%	10%	14%
Recurrent PEP use	5%			6%	2%	7%	3%
Recent STI	4%			5%	5%	0%	5%
Ongoing IPV/GBV	2%			0%	2%	0%	0%
Injection drug use	1%			0%	0%	5%	2%

Percentage of pharmacy PrEP clients

PPI: Definition of study outcomes



Days since PrEP initiation

(Ortblad KF, et. al., CROI 2022)

PPI: Definition of study outcomes



Days since PrEP initiation

On-time continuation:

Refilling PrEP no more than 15 days after a scheduled visit Stopping and restarting PrEP: Refilling PrEP >15 days after a scheduled visit

(Ortblad KF, et. al., CROI 2022)

PPI: PrEP initiation & continuation



A

(Ortblad KF, et. al., CROI 2022)

PPI: PrEP initiation & continuation, by sex/age





(Ortblad KF, et. al., CROI 2022)

Acceptability of pharmacy-based PrEP



Pharmacy-PrEP refill pilot **Pharmacy-PrEP** initiation pilot 0.6% 99% Liked pharmacy-based PrEP delivery 42% 58% 99% 29% 0.6%, 0.6% Pharmacy PrEP is easy/not complicated 71% 100% 42% 58% Like to continue pharmacy-based PrEP 1.9%, 1.3% 42% 97% 58% Would recommend pharmacy PrEP

Both men and women

Percentage of pharmacy clients

Strongly disagree Disagree	Neither agree nor disagree	Agree	Strongly agree
----------------------------	-------------------------------	-------	----------------

Acceptability of pharmacy-based PrEP





Percentage of pharmacy clients

Strongly disagree Disagree Neither agree nor disagree	Agree	Strongly agree
---	-------	----------------

Willingness to pay (KES)



	Pharmacy PrE (N=1	P Refill (PPR) 106)	Pharmacy PrEP Initiation (PPI) (N=287)		
% Clients willing to pay anything	88 (83%)		277 (97%)		
Women	N=57/63 (90%)		N=120/123 (98%)		
Men	N=31/43	3 (72%)	N=157/164 (96%)		
Amount willing to pay (KES)	Median (IQR)	Mean (STD)	Median (IQR)	Mean (STD)	
Women	200 (100-300)	228 (173)	300 (200-400)	354 (309)	
Men	300 (175-400)	282 (133)	300 (200-500)	354 (308)	

Willingness to pay (USD)



	Pharmacy PrE (N=1	P Refill (PPR) 106)	Pharmacy PrEP Initiation (PPI) (N=287)		
% Clients willing to pay anything	88 (83%)		277 (97%)		
Women	N=57/63 (90%)		N=120/123 (98%)		
Men	N=31/43	3 (72%)	N=157/164 (96%)		
Amount willing to pay (USD)	Median (IQR)	Mean (STD)	Median (IQR)	Mean (STD)	
Women	1.81 (0.90-2.71)	2.06 (1.56)	2.71 (1.81-3.61)	3.20 (2.79)	
Men	2.71 (1.58-3.61)	2.55 (1.20)	2.71 (1.81-4.52)	3.20 (2.78)	

Summary of findings

- Clients that initiate PrEP at clinics may have already overcome barriers to PrEP access there and prefer refilling PrEP at clinics; stressing the need for stand-alone models of pharmacy-delivered PrEP services to reach new populations.
- A standalone model of pharmacy-based PrEP delivery reached men who could benefit from PrEP services, as indicated by their high prevalence of recent behaviors associated with risk of HIV acquisition.
- A standalone model of pharmacy-delivered PrEP services resulted in high PrEP continuation among older men (≥25 years old); continuation that exceeds that often seen at public clinics.
- Pharmacy-delivered PrEP services were acceptable, and clients were willing to pay.
- Barriers to scale-up include lack of evidence on effectiveness, costs associated with delivery, and regulatory barriers surrounding HIVST for prescribing (research ongoing).

Future research: cRCT trial

- A four-arm cluster-randomized controlled trial (cRCT) testing different models of cost sharing to support pharmacy-delivered PrEP services in Kenya
- Trial enrollment begins May 2023!



Thank you!

Acknowledgements:

Participating providers and clients, research assistants, Kenya National AIDS & STI Control Program (NASCOP), Kenya Pharmacy and Poisons Board (PPB)

Fundings:

 National Institute for Mental Health (R34MH120106, PI: K Ortblad; P30 Al027757, PI: C Celum; R00MH121166, PI: K Ortblad)





